Rhythm Pharmaceuticals, Inc.

RYTM

NASDAQ

Healthcare

Biotechnology

Boston, MA, US283 employeesrhythmtx.com

$86.33

-1.79(-2.04%)

Mkt Cap $5.9B

$54.96

$117.62

52-Week Range

At a Glance

AI-generated

Revenue breakdown: Product (99.6%), License (0.4%).

8-K

Rhythm Pharmaceuticals elected Kimberly J. Popovits as a non-employee Class II director and accepted Edward T. Mathers' resignation from the Board, both effective April 1, 2026.

$5.9B

Market Cap

$194M

Revenue

-$201M

Net Income

Employees283

Fundamentals

How The Business Makes Money

Revenue by Segment

Product99.6%($1.6B)

License0.4%($7M)

Revenue by Geography

US72.6%($584M)

Non Us27.4%($220M)

Activity

What Changed Recently

Management Change

Apr 2, 2026

. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers On April

Financial Results

Feb 25, 2026

of this Current Report (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, a

Regulation FD

Mar 19, 2026

of this Current Report on Form 8-K (including Exhibits 99.1 and 99.2 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities E

Regulation FD

Mar 1, 2026

. Regulation FD Disclosure. On March 1, 2026, Rhythm Pharmaceuticals, Inc. (“Rhythm”) issued a press release announcing additional data from its global Phase 3

Financial Results+3 More

Jan 8, 2026

of this Current Report on Form 8-K (including Exhibit 99.1 ) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as a

Peer Companies

Company	Price	Change	Market Cap	P/E
RVMDRevolution Medicines, Inc...	$99.12	+0.49%	$19.6B	-16.2
NUVLNuvalent, Inc.	$105.04	-0.57%	$7.7B	-17.0
ACLXArcellx, Inc.	$114.77	+0.02%	$6.7B	-28.2
PTGXProtagonist Therapeutics,...	$103.85	+0.18%	$6.6B	-48.1
AKROAKRO	$54.65	+0.00%	$4.5B	—
KNSAKiniksa Pharmaceuticals, ...	$48.76	+1.31%	$3.6B	57.9
RLAYRelay Therapeutics, Inc.	$12.56	+16.67%	$2.2B	-6.1
SNDXSyndax Pharmaceuticals, I...	$25.08	+5.04%	$2.2B	-7.3

Analyst View

Company Profile

CIK0001649904

ISINUS76243J1051

CUSIP76243J105

Phone857 264 4280

Address222 Berkeley Street, Boston, MA, 02116, US

SEC EDGAR